Pilot study of pentoxifylline in hepatopulmonary syndrome

Liver Transplantation

Volumn 14, Issue 8, 2008, Pages 1199-1203

  Tanikella, Rajasekhar ^a   Philips, George M ^b   Faulk, Dorothy K ^a   Kawut, Steven M ^c,d   Fallon, Michael B ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c NONE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; PENTOXIFYLLINE; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; ASCITES; BLEEDING; BLURRED VISION; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEPATITIS C VIRUS; HEPATOPULMONARY SYNDROME; HUMAN; HYPOXEMIA; INFECTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ALVEOLUS OXYGEN TENSION; MALE; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOMITING;

AGED; BLOOD GAS ANALYSIS; FEMALE; HEPATOPULMONARY SYNDROME; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49649102089     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21482     Document Type: Article

References (15)

1. Rodríguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47:897-902.
2. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995;122:521-529.
3. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993;104:515-521.
4. Lange PA, Stoller JK. The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med 1996;17: 115-123.
5. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-614.
6. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001: 164:879-885.
7. Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002;166:514-517.
8. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
9. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48:465-470.
10. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004;23:752-758.
11. Zhang J, Ling Y, Tang L, Luo B, Chacko BK, Patel RP, Fallon MB. Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol 2007; 102:949-955.
12. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-2368.
13. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004;19:79-88.
14. Rodriguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary-hepatic vascular disorders. Eur Respir J 2004;24: 861-880.
15. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-196.